93 related articles for article (PubMed ID: 15136236)
1. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study.
Thompson MA; Kyle RA; Melton LJ; Plevak MF; Rajkumar SV
Haematologica; 2004 May; 89(5):626-8. PubMed ID: 15136236
[TBL] [Abstract][Full Text] [Related]
2. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
3. Risk of monoclonal gammopathy of undetermined significance: a case-referent study.
Pasqualetti P; Collacciani A; Casale R
Am J Hematol; 1996 Jul; 52(3):217-20. PubMed ID: 8756092
[TBL] [Abstract][Full Text] [Related]
4. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans.
Khurana V; Caldito G; Ankem M
Urology; 2008 Jan; 71(1):118-22. PubMed ID: 18242378
[TBL] [Abstract][Full Text] [Related]
5. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
8. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
10. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital].
Uchida M; Taida N; Kanao M; Kagamihara H; Kuwajima M
Rinsho Byori; 2004 Jul; 52(7):574-9. PubMed ID: 15344556
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Anagnostopoulos A; Galani E; Gika D; Sotou D; Evangelopoulou A; Dimopoulos MA
Ann Hematol; 2004 Oct; 83(10):658-60. PubMed ID: 15278296
[TBL] [Abstract][Full Text] [Related]
12. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients.
van Ree RM; de Vries AP; Oterdoom LH; The TH; Gansevoort RT; Homan van der Heide JJ; van Son WJ; Ploeg RJ; de Jong PE; Gans RO; Bakker SJ
Nephrol Dial Transplant; 2005 Nov; 20(11):2524-31. PubMed ID: 16115856
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
14. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
15. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Arnaud C; Burger F; Steffens S; Veillard NR; Nguyen TH; Trono D; Mach F
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1231-6. PubMed ID: 15790934
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein (CRP)-lowering agents.
Prasad K
Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
[TBL] [Abstract][Full Text] [Related]
17. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
18. Smoking, obesity, and statin therapy in the prognosis of prostate cancer.
Daniell HW
J Clin Oncol; 2010 Nov; 28(31):e643; author reply e645-6. PubMed ID: 20876422
[No Abstract] [Full Text] [Related]
19. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
